JP2005521651A - ピロリドンカルボキサミド類 - Google Patents

ピロリドンカルボキサミド類 Download PDF

Info

Publication number
JP2005521651A
JP2005521651A JP2003560008A JP2003560008A JP2005521651A JP 2005521651 A JP2005521651 A JP 2005521651A JP 2003560008 A JP2003560008 A JP 2003560008A JP 2003560008 A JP2003560008 A JP 2003560008A JP 2005521651 A JP2005521651 A JP 2005521651A
Authority
JP
Japan
Prior art keywords
rac
carboxamide
phenyl
oxopyrrolidine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003560008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521651A5 (https=
Inventor
イスラー，マルクス
ジラー，トーマス
シュワルム，ギュンター
ステガー，マティアス
ヒルパート，カート
ヴァルデネール，オリヴァー
ブレウ，フォルカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2005521651A publication Critical patent/JP2005521651A/ja
Publication of JP2005521651A5 publication Critical patent/JP2005521651A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003560008A 2001-12-31 2002-12-27 ピロリドンカルボキサミド類 Pending JP2005521651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH23812001 2001-12-31
CH0200429 2002-08-05
PCT/CH2002/000725 WO2003059905A1 (de) 2001-12-31 2002-12-27 Pyrrolidon-carboxamide

Publications (2)

Publication Number Publication Date
JP2005521651A true JP2005521651A (ja) 2005-07-21
JP2005521651A5 JP2005521651A5 (https=) 2009-11-26

Family

ID=25705687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003560008A Pending JP2005521651A (ja) 2001-12-31 2002-12-27 ピロリドンカルボキサミド類

Country Status (8)

Country Link
EP (1) EP1463724A1 (https=)
JP (1) JP2005521651A (https=)
KR (1) KR20040072697A (https=)
CN (1) CN100534990C (https=)
AU (1) AU2002350366A1 (https=)
CA (1) CA2471620A1 (https=)
MX (1) MXPA04006458A (https=)
WO (1) WO2003059905A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008101016A (ja) * 2005-08-09 2008-05-01 Daiichi Sankyo Co Ltd 新規セルコスポラミド誘導体
JP2012500834A (ja) * 2008-08-29 2012-01-12 ゼンション・リミテッド 新規なカリウムチャネルブロッカー
JP2017530192A (ja) * 2014-09-14 2017-10-12 ナノシンソンズ リミティド ライアビリティ カンパニー ピロリドン誘導体、オリゴマー及びポリマー

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
WO2007018193A1 (ja) * 2005-08-09 2007-02-15 Daiichi Sankyo Company, Limited 新規セルコスポラミド誘導体
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
EP2480531B1 (en) * 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
EP3126346B1 (en) * 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001085714A1 (en) * 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB856452A (en) * 1957-06-27 1960-12-14 Bayer Ag Protective agents against textile pests, mould and bacteria
US5281612A (en) * 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
DE69025418T2 (de) * 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001085714A1 (en) * 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008101016A (ja) * 2005-08-09 2008-05-01 Daiichi Sankyo Co Ltd 新規セルコスポラミド誘導体
JP2012500834A (ja) * 2008-08-29 2012-01-12 ゼンション・リミテッド 新規なカリウムチャネルブロッカー
JP2015120710A (ja) * 2008-08-29 2015-07-02 ゼンション・リミテッドＸｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ 新規なカリウムチャネルブロッカー
JP2017014267A (ja) * 2008-08-29 2017-01-19 日本たばこ産業株式会社 新規なカリウムチャネルブロッカー
JP2017530192A (ja) * 2014-09-14 2017-10-12 ナノシンソンズ リミティド ライアビリティ カンパニー ピロリドン誘導体、オリゴマー及びポリマー

Also Published As

Publication number Publication date
WO2003059905A1 (de) 2003-07-24
EP1463724A1 (de) 2004-10-06
CN100534990C (zh) 2009-09-02
CN1610678A (zh) 2005-04-27
AU2002350366A1 (en) 2003-07-30
MXPA04006458A (es) 2004-10-04
KR20040072697A (ko) 2004-08-18
CA2471620A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
JP2005521651A (ja) ピロリドンカルボキサミド類
CN101679239B (zh) 组蛋白脱乙酰酶抑制剂
AU2008206759B2 (en) Nicotinic acetylcholine receptor modulators
RU2298002C2 (ru) Производные хинолина в качестве антагонистов npy
JP5580364B2 (ja) 医薬として活性なピロリジン誘導体
JPH08508738A (ja) ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体
JPWO2008059854A1 (ja) ピペリジン誘導体またはその塩
US7576120B2 (en) Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them
JP2007510702A (ja) 代謝性疾患の処置に有用な１１−β−ＨＳＤ１阻害剤としてのＮ−アシル化−３−（ベンゾイル）−ピロリジン
CZ151895A3 (en) Aminomethylindanes, -benzofurans and -benzothiophenes, their use and a pharmaceutical preparation
EP1385840B1 (en) Sulfonamides
KR20000005505A (ko) 피페리딘 및 피롤리딘
CN1956962B (zh) 四氢异喹啉磺酰胺衍生物，其制备方法及其在治疗中的应用
JP2007501823A (ja) ２−アミノ−５−ベンゾイルチアゾールなるｎｐｙアンタゴニスト
CN101014573A (zh) 5－ht7受体拮抗剂
US7067549B2 (en) Pyrrolidone carboxamides
JP5142152B2 (ja) ４，５−ジアリールピロール誘導体、この調製方法および治療におけるこの使用
KR101152659B1 (ko) 세로토닌 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 동시에 가지는 설폰아마이드 화합물
EP2108012A2 (fr) Derives de n-(4-cyano-l h-p yrazol-3 -yl)methylamine substitues, leur preparation et leur application en therapeutique
RU2296757C2 (ru) Производные хиназолина
FR2908766A1 (fr) Derives de pyrrole,leur preparation et leur utilisation en therapeutique.
US20040082566A1 (en) Pyrrolidine sulfonamides
JPH11180979A (ja) 環状アミン誘導体
JP2001516745A (ja) 抗痙攣薬としての置換イソキノリン
TWI295286B (en) (2s)-2-[(2-oxo-4-propylpyrrolidinyl)butanamides and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100427